MPR- Medical Professionals Reference
@medicalprofref.bsky.social
MPR provides daily drug news and industry-supported drug information & education. Download our drug reference and clinical tools app today!
Drawing backlash from multiple medical organizations, the CDC website has been updated to suggest a vaccine-autism link. In his January confirmation hearing RFK Jr said he would not impose his personal antivax views. ➡️ www.empr.com/news/medical...
Medical Societies Condemn CDC Update Suggesting Vaccine-Autism Link
According to the US Department of Health and Human Services, research plans to investigate all the possible causes of autism are in the works.
www.empr.com
November 21, 2025 at 7:31 PM
Drawing backlash from multiple medical organizations, the CDC website has been updated to suggest a vaccine-autism link. In his January confirmation hearing RFK Jr said he would not impose his personal antivax views. ➡️ www.empr.com/news/medical...
Tonmya (cyclobenzaprine HCl sublingual tablets) is now commercially available, the first new FDA-approved fibromyalgia treatment in over 15 years. #Fibromyalgia #DrugApprovals #NewDrug www.empr.com/news/fibromy...
Fibromyalgia Treatment Tonmya Now Available
Tonmya is a once-daily sublingual tablet of cyclobenzaprine HCI taken at bedtime for the treatment of fibromyalgia.
www.empr.com
November 17, 2025 at 8:48 PM
Tonmya (cyclobenzaprine HCl sublingual tablets) is now commercially available, the first new FDA-approved fibromyalgia treatment in over 15 years. #Fibromyalgia #DrugApprovals #NewDrug www.empr.com/news/fibromy...
October 2025 Drug Approvals: Our at-a-glance essential prescribing update. ➡️ www.empr.com/news/october...
November 14, 2025 at 9:14 PM
October 2025 Drug Approvals: Our at-a-glance essential prescribing update. ➡️ www.empr.com/news/october...
The FDA has fully approved Komzifti (ziftomenib), the first and only once-daily oral menin inhibitor, for adults with R/R NPM1-mutated AML. www.empr.com/news/komzift...
Komzifti Approved for Adults With R/R NPM1-Mutated AML
The approval was based on data from the single-arm, open-label phase 2 KOMET-001 trial, which evaluated ziftomenib, a menin inhibitor, in adults with R/R AML with an NPM1 mutation.
www.empr.com
November 13, 2025 at 9:21 PM
The FDA has fully approved Komzifti (ziftomenib), the first and only once-daily oral menin inhibitor, for adults with R/R NPM1-mutated AML. www.empr.com/news/komzift...
Get yourself up to date on Lynkuet — a treatment approved for vasomotor symptoms due to menopause — with our InsightRx interview with trial investigator Dr JoAnn Pinkerton. www.empr.com/news/lynkuet...
November 12, 2025 at 8:42 PM
Get yourself up to date on Lynkuet — a treatment approved for vasomotor symptoms due to menopause — with our InsightRx interview with trial investigator Dr JoAnn Pinkerton. www.empr.com/news/lynkuet...
Law feature: This month's case resulted in a jury finding in favor of the patient to the tune of $40 million dollars and apportioned the pharmacist's fault at 2%. www.empr.com/features/dos...
Dosing Error Goes Unrecognized Leading to Serious Patient Harm
Over the course of the patient's treatment, there were opportunities to recognize the error and prevent the patient's catastrophic results.
www.empr.com
November 11, 2025 at 8:46 PM
Law feature: This month's case resulted in a jury finding in favor of the patient to the tune of $40 million dollars and apportioned the pharmacist's fault at 2%. www.empr.com/features/dos...
Lynkuet was recently approved to treat vasomotor symptoms due to menopause, hear all about it in our interview with one of the trial investigators in our latest InsightRx! www.empr.com/news/lynkuet...
Lynkuet® (elinzanetant) for the Treatment of Vasomotor Symptoms Due to Menopause
JoAnn Pinkerton MD, discusses Lynkuet® (elinzanetant), a new FDA-approved treatment for moderate to severe vasomotor symptoms due to menopause. Dr
www.empr.com
November 3, 2025 at 9:34 PM
Lynkuet was recently approved to treat vasomotor symptoms due to menopause, hear all about it in our interview with one of the trial investigators in our latest InsightRx! www.empr.com/news/lynkuet...
Current evidence for the use of leucovorin to treat autism symptoms is mainly limited to small studies and case reports in children with CFD.
www.empr.com/news/aap-cur...
www.empr.com/news/aap-cur...
October 31, 2025 at 5:36 PM
Current evidence for the use of leucovorin to treat autism symptoms is mainly limited to small studies and case reports in children with CFD.
www.empr.com/news/aap-cur...
www.empr.com/news/aap-cur...
From ACR 2025: biologic disease-modifying antirheumatic drugs (DMARDs) appear to be tied to worse COVID-19 outcomes than conventional DMARDs. www.empr.com/reports/biol...
Biologic DMARDs Linked to Worse COVID-19 Outcomes in RA Patients
Researchers compared COVID-19 outcomes in rheumatoid arthritis patients treated with biologic vs conventional DMARDs.
www.empr.com
October 28, 2025 at 7:58 PM
From ACR 2025: biologic disease-modifying antirheumatic drugs (DMARDs) appear to be tied to worse COVID-19 outcomes than conventional DMARDs. www.empr.com/reports/biol...
This Class II Neutrogena recall involves 1312 cases of the 50-count, 25-pack towelettes. www.empr.com/news/neutrog...
October 28, 2025 at 3:30 PM
This Class II Neutrogena recall involves 1312 cases of the 50-count, 25-pack towelettes. www.empr.com/news/neutrog...
Prefilled single-dose autoinjector now available for treatment of migraine and cluster headache. www.empr.com/news/brekiya...
Brekiya Now Available for Migraine, Cluster Headache Treatment
Brekiya is available with prescription exclusively through Walgreens Specialty Pharmacy and Sterling Specialty Pharmacy.
www.empr.com
October 27, 2025 at 8:19 PM
Prefilled single-dose autoinjector now available for treatment of migraine and cluster headache. www.empr.com/news/brekiya...
🎧 Latest MPR Pod out now!
🔹 Label changes for tranexamic acid;
🔸 New approval for Tezspire;
🔹 Psychedelic gains Breakthrough Tx status for depression;
🔸 Oral semaglutide approved to reduce MACE risk in T2DM; and
🔹 Gazyva approved for lupus nephritis.
www.empr.com/news/mpr-wee...
🔹 Label changes for tranexamic acid;
🔸 New approval for Tezspire;
🔹 Psychedelic gains Breakthrough Tx status for depression;
🔸 Oral semaglutide approved to reduce MACE risk in T2DM; and
🔹 Gazyva approved for lupus nephritis.
www.empr.com/news/mpr-wee...
MPR Weekly Dose Podcast #254
Label changes for tranexamic acid; new approval for Tezspire; psychedelic gains Breakthrough Tx for depression; oral semaglutide approved to reduce MACE risk in T2DM; Gazyva approved for lupus.
www.empr.com
October 24, 2025 at 8:03 PM
🎧 Latest MPR Pod out now!
🔹 Label changes for tranexamic acid;
🔸 New approval for Tezspire;
🔹 Psychedelic gains Breakthrough Tx status for depression;
🔸 Oral semaglutide approved to reduce MACE risk in T2DM; and
🔹 Gazyva approved for lupus nephritis.
www.empr.com/news/mpr-wee...
🔹 Label changes for tranexamic acid;
🔸 New approval for Tezspire;
🔹 Psychedelic gains Breakthrough Tx status for depression;
🔸 Oral semaglutide approved to reduce MACE risk in T2DM; and
🔹 Gazyva approved for lupus nephritis.
www.empr.com/news/mpr-wee...
Findings showed the study did not meet its primary endpoint of preventing CMV infection in seronegative participants. www.empr.com/news/moderna...
October 23, 2025 at 8:07 PM
Findings showed the study did not meet its primary endpoint of preventing CMV infection in seronegative participants. www.empr.com/news/moderna...
Tylenol maker urges regulators to not add autism warning to label citing a lack of scientific evidence. www.empr.com/news/fda-and...
FDA and Kenvue Say No Autism Link to Tylenol Use During Pregnancy
The maker of Tylenol is urging the FDA to reject autism warning requests for the drug's use in pregnancy.
www.empr.com
October 23, 2025 at 2:12 PM
Tylenol maker urges regulators to not add autism warning to label citing a lack of scientific evidence. www.empr.com/news/fda-and...
Drug combo gets Priority Review for possible adjuvant treatment in patients with muscle-invasive bladder cancer. www.empr.com/news/enfortu...
October 22, 2025 at 8:01 PM
Drug combo gets Priority Review for possible adjuvant treatment in patients with muscle-invasive bladder cancer. www.empr.com/news/enfortu...
There have been continued reports of tranexamic acid being erroneously administered resulting in serious harm and prompting this label change. www.empr.com/news/fda-adm...
FDA: Administration Mix-Ups Prompt Tranexamic Acid Injection Label Changes
The alert was issued after medication error cases of tranexamic acid injection administered neuraxially instead of the intended local anesthetic were reported.
www.empr.com
October 22, 2025 at 6:34 PM
There have been continued reports of tranexamic acid being erroneously administered resulting in serious harm and prompting this label change. www.empr.com/news/fda-adm...
Participants in a social anxiety treatment trial were tasked with delivering a 5 minutes speech with 2 minutes notice. The results did not match the primary endpoint. www.empr.com/news/negativ...
October 21, 2025 at 3:37 PM
Participants in a social anxiety treatment trial were tasked with delivering a 5 minutes speech with 2 minutes notice. The results did not match the primary endpoint. www.empr.com/news/negativ...
From 2005 to 2024, an estimated 3,112 pickleball-related ocular injuries occurred, with 1,262 injuries occurring in 2024 alone.
www.empr.com/news/pickleb...
www.empr.com/news/pickleb...
October 20, 2025 at 3:46 PM
From 2005 to 2024, an estimated 3,112 pickleball-related ocular injuries occurred, with 1,262 injuries occurring in 2024 alone.
www.empr.com/news/pickleb...
www.empr.com/news/pickleb...
A psychedelic nasal spray has been designated a Breakthrough therapy by the FDA. www.empr.com/news/intrana...
October 17, 2025 at 7:30 PM
A psychedelic nasal spray has been designated a Breakthrough therapy by the FDA. www.empr.com/news/intrana...
Jascayd was recently approved to treat idiopathic pulmonary fibrosis, we spoke to one of the trial investigators it in our latest InsightRx. www.empr.com/news/jascayd...
October 17, 2025 at 6:55 PM
Jascayd was recently approved to treat idiopathic pulmonary fibrosis, we spoke to one of the trial investigators it in our latest InsightRx. www.empr.com/news/jascayd...
📢 Latest MPR Podcast out now!
🔹 New treatment approved for bipolar I disorder;
🔸 Rinvoq IBD indications updated;
🔴 Blood-based test for early detection of amyloid pathology; and
💊 Oral GLP-1 treatment continues to show promise in T2D.
www.empr.com/news/mpr-wee...
🔹 New treatment approved for bipolar I disorder;
🔸 Rinvoq IBD indications updated;
🔴 Blood-based test for early detection of amyloid pathology; and
💊 Oral GLP-1 treatment continues to show promise in T2D.
www.empr.com/news/mpr-wee...
October 17, 2025 at 6:09 PM
📢 Latest MPR Podcast out now!
🔹 New treatment approved for bipolar I disorder;
🔸 Rinvoq IBD indications updated;
🔴 Blood-based test for early detection of amyloid pathology; and
💊 Oral GLP-1 treatment continues to show promise in T2D.
www.empr.com/news/mpr-wee...
🔹 New treatment approved for bipolar I disorder;
🔸 Rinvoq IBD indications updated;
🔴 Blood-based test for early detection of amyloid pathology; and
💊 Oral GLP-1 treatment continues to show promise in T2D.
www.empr.com/news/mpr-wee...
Review period extended for novel Hunter syndrome treatment. www.empr.com/news/fda-ext...
FDA Extends Review for Tividenofusp Alfa for Hunter Syndrome
The extension was necessary to review updated clinical pharmacology information submitted by Denali.
www.empr.com
October 15, 2025 at 8:35 PM
Review period extended for novel Hunter syndrome treatment. www.empr.com/news/fda-ext...
Law Feature: Jury awards enormous sum to patient who suffered devastating consequences from medical procedure. www.empr.com/features/jur...
Jury Sides With Plaintiff's Medical Expert in Unanimous $60 Million Verdict
This month’s case resulted in a large monetary verdict against the physician, possibly a record-breaking sum in the New York country where it took place.
www.empr.com
October 14, 2025 at 3:11 PM
Law Feature: Jury awards enormous sum to patient who suffered devastating consequences from medical procedure. www.empr.com/features/jur...
Rhapsido was recently approved for chronic spontaneous urticaria, find out all about it from one of the clinical trial investigators on MPR's InsightRx. www.empr.com/news/rhapsid...
October 10, 2025 at 5:09 PM
Rhapsido was recently approved for chronic spontaneous urticaria, find out all about it from one of the clinical trial investigators on MPR's InsightRx. www.empr.com/news/rhapsid...
Immunization schedule changes approved for COVID-19 vaccines. www.empr.com/news/cdc-app...
October 7, 2025 at 6:19 PM
Immunization schedule changes approved for COVID-19 vaccines. www.empr.com/news/cdc-app...